Omadacycline for Community-Acquired Bacterial Pneumonia

Omadacycline for Community-Acquired Bacterial Pneumonia

Omadacycline is a new antimicrobial that is related to tetracyclines and is active against a broad range of pathogens. In this randomized, controlled trial involving 774 adults, omadacycline was found to be noninferior to moxifloxacin in the treatment of community-acquired bacterial pneumonia.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 380; no. 6; pp. 517 - 527
Main Authors: Stets, Roman, Popescu, Monica, Gonong, Joven R, Mitha, Ismail, Nseir, William, Madej, Andrzej, Kirsch, Courtney, Das, Anita F, Garrity-Ryan, Lynne, Steenbergen, Judith N, Manley, Amy, Eckburg, Paul B, Tzanis, Evan, McGovern, Paul C, Loh, Evan
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 07-02-2019
Subjects:
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - therapeutic use
Antibiotics
Bacteria
Bacteria - isolation & purification
Clinical trials
Community-Acquired Infections - drug therapy
Cough
Diarrhea
Double-Blind Method
Drug Administration Schedule
Drug dosages
Dyspnea
Female
Hospitalization
Humans
Infusions, Intravenous
Intention to Treat Analysis
Male
Middle Aged
Moxifloxacin
Moxifloxacin - adverse effects
Moxifloxacin - therapeutic use
Pain
Patients
Pharmaceuticals
Pneumonia
Pneumonia, Bacterial - drug therapy
Pneumonia, Bacterial - microbiology
Respiration
Sputum
Statistical analysis
Streptococcus infections
Tetracyclines - adverse effects
Tetracyclines - therapeutic use
United States > US
Europe
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Omadacycline is a new antimicrobial that is related to tetracyclines and is active against a broad range of pathogens. In this randomized, controlled trial involving 774 adults, omadacycline was found to be noninferior to moxifloxacin in the treatment of community-acquired bacterial pneumonia.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Undefined-2
ObjectType-News-4
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1800201